Mybiotics Pharma LTD
Yoshinori Oikawa is an accomplished executive with extensive experience in various leadership roles across multiple industries. Since December 2017, Yoshinori has served as Executive Chairman of Mybiotics Pharma LTD. Additionally, Yoshinori held the position of Representative Director and global management member at Aquarius Engines from January 2020 to March 2025, contributing to the development of the world's first commercially available linear engine designed for multiple fuels, including greener options. Yoshinori co-founded Cellergy bio and served as its CEO from April 2022 to May 2024, as well as co-founding a stealth-mode startup from January 2022 to March 2024. Previously, Yoshinori also served as Executive Chairman at CSP Advanced Solutions KK and held leadership positions at Audioburst K.K. and Audioburst, along with board roles at Emendo Biotherapeutics and Terafence Ltd. Yoshinori's academic background includes a BSc and MBA from The Hebrew University of Jerusalem, completed between 1986 and 1995.
This person is not in any teams
This person is not in any offices
Mybiotics Pharma LTD
MyBiotics innovative technologies; MyCrobeTM and SuperDonorTM allow us to be in the front of the microbiome field. Both technologies resolve the three critical factors in the probiotic development market. Delivery, Targeting and Colonization. MyCrobeTM and SuperDonorTM provide single or multi-bacterial combinations for targeted treatment, wholemicrobiome restoration and the first actual screening method to replace FMT microbiome transplantations. MyBiotics focus is to return the bacterial population to its healthy and balanced state by using live bacteria that will colonize and compete with the existent disease-promoting population.